2018 / 05

Next Paper
DOI: 10.24075/brsmu.2018.061

ORIGINAL RESEARCH

Targeted sequencing in patients with clinically diagnosed hereditary lipid metabolism disorder and acute coronary syndrome

Averkova AO1, Brazhnik VA2, Speshilov GI3,4, Rogozhina AA, Koroleva OS, Zubova EA2, Galyavich AS5, Tereshenko SN6, Boyeva OI7, Zateyshchikov DA2
About authors

1 Central State Medical Academy of the Department of Presidential Affairs of the Russian Federation, Moscow, Russia

2 City Clinical Hospital № 51, Moscow, Russia

3 Kharkevich Institute for Information Transmission Problems, RAS, Moscow

4 ReadSense OOO, Troitsk Center for Nanotechnologies of Rusnano Foundation for Nanotechnology Infrastructure and Educational Projects, Moscow

5 Kazan State Medical University, Kazan

6 National Medical Research Center for Cardiology, Moscow, Russia

7 Stavropol State Medical University, Stavropol

Correspondence should be addressed: Anastasia О. Averkova
Marshala Timoshenko 19, b. 1A, Moscow, 121359; ur.liam@keva

Received: 2018-09-30 Accepted: 2018-11-05 Published online: 2018-11-23
|
  1. Braenne I, Kleinecke M, Reiz B, Graf E, Strom T, Wieland T et al. Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction. Eur J Hum Genet. 2016; 24 (2): 191–7.
  2. Sharifi M, Futema M, Nair D, Humphries SE. Genetic Architecture of Familial Hypercholesterolaemia. Current Cardiology Reports. 2017; 19(5): 1–8.
  3. Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nature Reviews Disease Primers. 2017; (3): 1–20.
  4. Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M et al. Apolipoprotein B100 metabolism in autosomal- dominant hypercholesterolemia related to mutations in PCSK9. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004; 24 (8): 1448–53.
  5. Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012; 32 (7): 1585–95.
  6. Zatejshhikov DA, Volkova JeG, Guz IO, Evdokimova MA, Asejcheva OJu, Galjavich AS i dr. Lechenie bol'nyh, perenesshih ostryj koronarnyj sindrom, po dannym Rossijskogo mnogocentrovogo prospektivnogo nabljudatel'nogo issledovanija. Farmateka. 2009; (12): 109–13.
  7. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart Journal. 2016; 37 (39): 2999–3058.
  8. Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. British Medical Journal. 2008; (337): 1095.
  9. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17 (5): 405–24.
  10. Averkova AO, Brazhnik VA, Koroleva OS, Zubova EA, Rogozhina AA, Hasanov NR et al. Osobennosti porazheniya koronarnogo rusla i techeniya ostrogo koronarnogo sindroma u molodyh bol'nyh s semejnoj giperlipidemiej po dannym nablyudatel'nogo proekta ORAKUL II. Kompleksnye problemy serdechno-sosudistyh zabolevanij. Prilozhenie. 2017; 6 (4): 9.
  11. Usifo E, Leigh SEA, Whittall RA, Lench N, Taylor A, Yeats C et al. Low–Density Lipoprotein Receptor Gene Familial Hypercholesterolemia Variant Database: Update and Pathological Assessment. Annals of Human Genetics. 2012; 76 (5): 387–401.
  12. Bertolini S, Pisciotta L, Rabacchi C, Cefalu AB, Noto D, Fasano T et al. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis. 2013; 227 (2): 342–8.
  13. Pisciotta L, Priore Oliva C, Cefalu AB, Noto D, Bellocchio A, Fresa R et al. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis. 2006; 186 (2): 433–40.
  14. Wintjens R, Bozon D, Belabbas K, MBou F, Girardet JP, Tounian P A et al. Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France. Journal of lipid research. 2016; 57 (3): 482–91.
  15. Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H et al. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet. 2001; 69 (2): 278–90.
  16. De Backer G, Besseling J, Chapman J, Hovingh GK, Kastelein JJP, Kotseva K et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis. 2015; 241 (1): 169–75.
  17. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European Heart Journal. 2013; 34 (45): 3478–90a.
  18. Ezhov MV, Sergienko IV, Duplyakov DV, Abashina OE, Kachkovskiy MA, Shaposhnik II et al. Rezul'taty Rossijskoj nauchno- issledovatel'skoj programmy po diagnostike i lecheniyu bol'nyh semejnoj giperholesterinemiej. Vysokaya rasprostranennost', nizkaya informirovannost', plohaya priverzhennost'. Ateroskleroz i dislipidemii. 2017; (2): 5–15.
  19. Zaharova FM, Tatishcheva YA, Golubkov VI, Lipoveckij BM, Konstantinov VO, Denisenko AD et al. Semejnaya giperholesterinemiya v Sankt-Peterburge: raznoobrazie mutacij svidetel'stvuet ob otsutstvii vyrazhennogo ehffekta osnovatelya. Genetika. 2007; 43 (9): 1255–62.
  20. Korneva VA, Bogoslovskaya TY, Kuznecova TY, Mandelshtam MY, Vasilev BV. Semejnaya giperholesterinemiya, obsulovlennaya novoj mutaciej gena receptorov lipoproteinov nizkoj plotnosti. Klinicheskaya medicina. 2014; (7): 49–53.
  21. Shakhtshneider EV, Makarenkova KV, Astrakova KS, Ivanoshchuk DE, Orlov PS, Ragino YI et al. Targetnoe sekvenirovanie gena PCSK9 u pacientov semejnoj giperholesterinemiej v Rossii. Kardiologiya. 2017; (6): 46–51.
  22. Kosenko T, Golder M, Leblond G, Weng W, Lagace TA. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. The Journal of biological chemistry. 2013; 288 (12): 8279–88.
  23. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. Jama. 2007; 298 (11): 1300–11.
  24. Luo JQ, Ren H, Banh HL, Liu MZ, Xu P, Fang PF et al. The Associations between Apolipoprotein E Gene Epsilon2/Epsilon3/ Epsilon4 Polymorphisms and the Risk of Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus. Frontiers in physiology. 2017; (8): 1031.
  25. Shakhtshneider EV, Ragino YI, Chernjavski AM, Kulikov IV, Ivanova MV, Voevoda MI. Apolipoprotein E gene polymorphism in men with coronary atherosclerosis in Siberia. Bulletin of experimental biology and medicine. 2011; 150 (3): 355–8.
  26. Vandrovcova J, Thomas ER, Atanur SS, Norsworthy PJ, Neuwirth C, Tan Y et al. The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia. Genet Med. 2013; 15 (12): 948–57.